G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30

American Journal of Translational Research

Volumn 7, Issue 5, 2015, Pages 967-975

  Liu, Yu ^a   Du, Fei Ya ^a   Chen, Wei ^a   Fu, Pei Fen ^a   Yao, Min Ya ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Epithelial mesenchymal transition; G15; GPR30

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DOXORUBICIN; EDOXUDINE; G PROTEIN COUPLED RECEPTOR 30; G15; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; WESTERN BLOTTING;

EID: 84936767402     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. [1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. [2] Engelhardt EG, Garvelink MM, de Haes JH, van der Hoeven JJ, Smets EM, Pieterse AH, Stiggel-bout AM. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol 2014; 32: 238-250.
3. [3] Miles DW, Dieras V, Cortes J, Duenne AA, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-neg-ative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24: 2773-2780.
4. [4] de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken PM, Sonke GS, Rodenhuis S, Wes-sels LF. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat 2013; 137: 213-223.
5. [5] Croker AK, Allan AL. Inhibition of aldehyde de-hydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res Treat 2012; 133: 75-87.
6. [6] Hergovich A. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer. Breast Cancer Res 2012; 14: 326.
7. [7] Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ. Role of JNK in mammary gland development and breast cancer. Cancer Res 2012; 72: 472-481.
8. [8] Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sand-bach JF. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012; 118: 2787-2795.
9. [9] Lee EK, Jeon WK, Chae MY, Hong HY, Lee YS, Kim JH, Kwon JY, Kim BC, Park SH. Decreased expression of glutaredoxin 1 is required for transforming growth factor-beta1-mediated epithelial-mesenchymal transition of EpRas mammary epithelial cells. Biochem Biophys Res Commun 2010; 391: 1021-1027.
10. [10] Masui T, Ota I, Yook JI, Mikami S, Yane K, Ya-manaka T, Hosoi H. Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int J Oncol 2014; 44: 693-699.
11. [11] Son H, Moon A. Epithelial-mesenchymal Transition and Cell Invasion. Toxicol Res 2010; 26: 245-252.
12. [12] Kwon JE, Jung WH, Koo JS. Molecules involved in epithelial-mesenchymal transition and epi-thelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis. Tumour Biol 2012; 33: 787-798.
13. [13] Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH, Du J. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplat-in-resistant lung cancer cells through AKT/be-ta-catenin/Snail signaling pathway. Eur J Pharmacol 2014; 723: 156-166.
14. [14] Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
15. [15] Pang Y, Thomas P. Involvement of estradiol-17beta and its membrane receptor, G protein coupled receptor 30 (GPR30) in regulation of oocyte maturation in zebrafsh, Danio rario. Gen Comp Endocrinol 2009; 161: 58-61.
16. [16] Kanda N, Watanabe S. 17beta-estradiol inhibits oxidative stress-induced apoptosis in kerati-nocytes by promoting Bcl-2 expression. J Invest Dermatol 2003; 121: 1500-1509.
17. [17] Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 2004; 123: 319-328.
18. [18] Vivacqua A, Bonofglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradi-ol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-646.
19. [19] Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, Yang G. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res 2013; 15: R114.
20. [20] Dennis MK, Burai R, Ramesh C, Petrie WK, Al-con SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Ar-terburn JB, Oprea TI, Prossnitz ER. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009; 5: 421-427.
21. [21] Bai LY, Weng JR, Hu JL, Wang D, Sargeant AM, Chiu CF. G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squa-mous carcinoma cells. Chem Biol Interact 2013; 206: 375-384.
22. [22] Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, Yin J, Yu Y, He Z. Chemoresistance to 5-fuorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012; 417: 679-685.
23. [23] Fatemian T, Chowdhury EH. Targeting Onco-genes and Tumor Suppressors genes to Mitigate Chemoresistance. Curr Cancer Drug Targets 2014; 14: 599-609.
24. [24] Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
25. [25] Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Pros-taglandins Other Lipid Mediat 2009; 89: 89-9 7.
26. [26] Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006; 12: 6359-6366.
27. [27] Smith HO, Leslie KK, Singh M, Qualls CR, Re-vankar CM, Joste NE, Prossnitz ER. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007; 196: 381-389.
28. [28] Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009; 114: 465-471.
29. [29] Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, Yin J, Yu Y, He Z. Chemoresistance to 5-fuorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012; 417: 679-685.
30. [30] Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L, Ouyang G. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011; 30: 4707-4720.
31. [31] Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD. A systems view of epi-thelial-mesenchymal transition signaling states. Clin Exp Metastasis 2011; 28: 137-155.
32. [32] Azhar M. Non-redundant tumour supressor functions of transforming growth factor beta in breast cancer. J Biosci 2001; 26: 9-12.
33. [33] Zhao H, Lo YH, Yu L, Wang SC. Overcoming resistance to fulvestrant (ICI182,780) by down-regulating the c-ABL proto-oncogene in breast cancer. Mol Carcinog 2011; 50: 383-389.
34. [34] Al SS, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mes-enchymal transition (Review). Int J Oncol 2011; 38: 1197-1217.